Investor Presentaiton

Rigosertib identified as lead PLK1 inhibitor in RDEB CSCC Percentage viability B 200- 150- 100- 50- RDEB SCC (n = 10) (n=10) Normal keratinocytes (n=4) ✰ SCCRDEB2 SCCRDEB3 SCCRDEB4 0- -4 -3 -2 log ON-01910, mmol/L 23 Clin Cancer Res March 7 2019 DOI:10.1158/1078-0432.CCR-18-2661. PMID: 30846478 Percentage viability 100- 50- -5-4-3 -2 log ON-01910, mmol/L 0 ONCONOVA THERAPEUTICS

View entire presentation